Navigation Links
Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Date:2/15/2008

NEW HAVEN, Conn., Feb. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that the Company had paid interest due February 15, 2008 on its 7.75% Convertible Senior Notes due 2012 (the "Notes"). The aggregate principal amount of the Notes is $60 million.

The Company paid $2,376,666.67 through the issuance of shares of its registered Common Stock. Approximately $2,376,345.60 was paid in 5,500,800 shares of Common Stock, based on today's closing bid price of $0.432, which is approximately equal to 91.68 shares of Common Stock per each $1,000 principal amount of Notes. Cash interest was paid in lieu of fractional shares.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk f
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals Announces Additions to Management Team
2. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
3. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
4. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast
5. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. Vion Pharmaceuticals Holds Special Meeting of Stockholders
7. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
8. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research and ... Transfection Technology Market - Global Industry Analysis, Size, Share, ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... nucleic acids (either DNA or RNA) into cells. This ... of cancer cells and protein metabolism by affecting the ...
(Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/10/2014)... London, UK (PRWEB) July 10, 2014 ... inaugural 21st Century Medicine Forum on ‘Commercialising Longevity ... scientists and entrepreneurs to the London Bioscience Innovation ... Biogerontology Research Foundation and Aging Analytics Ltd. The ... and investment in translational research for age-related disease, ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... production, announced today the appointment of Michael Bayer, MD, as Director, ... and clinical trial protocols for use by research centers conducting pre-clinical ... ... Diego, CA (PRWEB) January 30, 2009 -- Stemedica Cell Technologies ...
... of future electronic devices could shrink dramatically to one ... many tens of nanometers that characterize today,s most advanced elements ... walls, the ultrathin transition zones that separate regions of a ... , In a material called bismuth ferrite, an unusual compound ...
... this inaugural edition of the BBVA Foundation Frontiers of ... (Austria, 1952) and Ignacio Cirac (Manresa, 1965), "for their ... of the jury chaired by Theodor W. Hnsch, Nobel ... up vital new avenues for the development of quantum ...
Cached Biology Technology:Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services 2Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services 3Domain walls that conduct electricity 2Domain walls that conduct electricity 3Domain walls that conduct electricity 4Domain walls that conduct electricity 5Peter Zoller and Ignacio Cirac, awarded by the BBVA Foundation 2
(Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP ... Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and ... in United States District Court, Middle District of ... on behalf of a class consisting of all ... Provectus securities between December 17, 2013 and May ...
(Date:7/10/2014)... 2014 It is a great honor for ... of the world-renowned Thoracic and Cardiovascular surgeon, Mark E ... Dr. Ginsburg, with over 34 years of experience, is ... Good Samaritan Regional Medical Center. Dr. Ginsburg has been ... and is considered an expert in the implantation of ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... the blinding effects of diabetic retinopathy is pointing toward ... said. Interleukin-6, known to contribute to the ... inflammation of the retina, a first step in a ... working-age adults, MCG researchers reported online in Investigative ...
... Since the time of the earliest humans, people have ... our surroundings and searched for explanations for natural phenomena. ... questions remain to be answered. Although we understand core ... understanding of issues such as how plants maximize their photosynthetic ...
... SCOTTSDALE, Ariz. Jan. 13, 2010 Researchers ... have identified a way to predict which patients with ... The study, Tumor MicroRNA Biomarkers Associated with De ... presented today in San Diego at a joint conference ...
Cached Biology News:Discovery points toward anti-inflammation treatment for blinding disease 2Seeing the forest through the trees and seeing the trees through the leaves 2TGen-Scottsdale Healthcare researchers make breakthrough in lung cancer 2
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
Biology Products: